Hypothetical atopic dermatitis-myeloproliferative neoplasm syndrome

Frontiers in Immunology

Volumn 6, Issue AUG, 2015, Pages

  Kawakami, Toshiaki ^a,b   Ando, Tomoaki ^b   Kawakami, Yuko ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b RIKEN Center for Integrative Medical Sciences   (Japan)

Author keywords

Atopic dermatitis; Hematopoietic stem cell; Mast cell; Mouse models; Myeloproliferative neoplasm

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FILAGGRIN; STAT5 PROTEIN; THYMIC STROMAL LYMPHOPOIETIN;

ARTICLE; ATOPIC DERMATITIS; EPIDERMIS; FILAGGRIN GENE; GENE; GENE OVEREXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; KERATINOCYTE; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PATHOGENESIS; SIGNAL TRANSDUCTION; TH17 CELL;

EID: 84941284095     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00434     Document Type: Article

References (48)

1. Bieber T. Atopic dermatitis. N Engl J Med (2008) 358(14):1483-94. doi:10.1056/NEJMra074081.
2. Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med (2011) 365(14):1315-27. doi:10.1056/NEJMra1011040.
3. Margolis DJ, Apter AJ, Gupta J, Hoffstad O, Papadopoulos M, Campbell LE, et al. The persistence of atopic dermatitis and filaggrin (FLG) mutations in a US longitudinal cohort. J Allergy Clin Immunol (2012) 130(4):912-7. doi:10.1016/j.jaci.2012.07.008.
4. McAleer MA, Irvine AD. The multifunctional role of filaggrin in allergic skin disease. J Allergy Clin Immunol (2013) 131(2):280-91. doi:10.1016/j.jaci.2012.12.668.
5. De Benedetto A, Rafaels NM, McGirt LY, Ivanov AI, Georas SN, Cheadle C, et al. Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol (2011) 127(3):e1-7. doi:10.1016/j.jaci.2010.10.018.
6. Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. J Clin Invest (2004) 113(5):651-7. doi:10.1172/JCI21060.
7. Koga C, Kabashima K, Shiraishi N, Kobayashi M, Tokura Y. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol (2008) 128(11):2625-30. doi:10.1038/jid.2008.111.
8. Toda M, Leung DY, Molet S, Boguniewicz M, Taha R, Christodoulopoulos P, et al. Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions. J Allergy Clin Immunol (2003) 111(4):875-81. doi:10.1067/mai.2003.1414.
9. Choy DF, Hsu DK, Seshasayee D, Fung MA, Modrusan Z, Martin F, et al. Comparative transcriptomic analyses of atopic dermatitis and psoriasis reveal shared neutrophilic inflammation. J Allergy Clin Immunol (2012) 130(6):1335.e-43.e. doi:10.1016/j.jaci.2012.06.044.
10. Kawakami T, Ando T, Kimura M, Wilson BS, Kawakami Y. Mast cells in atopic dermatitis. Curr Opin Immunol (2009) 21(6):666-78. doi:10.1016/j.coi.2009.09.006.
11. Jin H, He R, Oyoshi M, Geha RS. Animal models of atopic dermatitis. J Invest Dermatol (2009) 129(1):31-40. doi:10.1038/jid.2008.106.
12. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol (2004) 172(5):2731-8. doi:10.4049/jimmunol.172.5.2731.
13. Shay T, Jojic V, Zuk O, Rothamel K, Puyraimond-Zemmour D, Feng T, et al. Conservation and divergence in the transcriptional programs of the human and mouse immune systems. Proc Natl Acad Sci U S A (2013) 110(8):2946-51. doi:10.1073/pnas.1222738110.
14. Emes RD, Goodstadt L, Winter EE, Ponting CP. Comparison of the genomes of human and mouse lays the foundation of genome zoology. Hum Mol Genet (2003) 12(7):701-9. doi:10.1093/hmg/ddg078.
15. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol (2011) 29(5):573-82. doi:10.1200/JCO.2010.29.8711.
16. Ishii T, Wang J, Zhang W, Mascarenhas J, Hoffman R, Dai Y, et al. Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. Blood (2009) 113(23):5942-50. doi:10.1182/blood-2008-09-179416.
17. Meixner A, Zenz R, Schonthaler HB, Kenner L, Scheuch H, Penninger JM, et al. Epidermal JunB represses G-CSF transcription and affects haematopoiesis and bone formation. Nat Cell Biol (2008) 10(8):1003-11. doi:10.1038/ncb1761.
18. Murthy A, Shao YW, Narala SR, Molyneux SD, Zuniga-Pflucker JC, Khokha R. Notch activation by the metalloproteinase ADAM17 regulates myeloproliferation and atopic barrier immunity by suppressing epithelial cytokine synthesis. Immunity (2012) 36(1):105-19. doi:10.1016/j.immuni.2012.01.005.
19. Franzke CW, Cobzaru C, Triantafyllopoulou A, Loffek S, Horiuchi K, Threadgill DW, et al. Epidermal ADAM17 maintains the skin barrier by regulating EGFR ligand-dependent terminal keratinocyte differentiation. J Exp Med (2012) 209(6):1105-19. doi:10.1084/jem.20112258.
20. Dumortier A, Durham AD, Di Piazza M, Vauclair S, Koch U, Ferrand G, et al. Atopic dermatitis-like disease and associated lethal myeloproliferative disorder arise from loss of Notch signaling in the murine skin. PLoS One (2010) 5(2):e9258. doi:10.1371/journal.pone.0009258.
21. Xiao W, Hong H, Kawakami Y, Kato Y, Wu D, Yasudo H, et al. Tumor suppression by phospholipase C-beta3 via SHP-1-mediated dephosphorylation of Stat5. Cancer Cell (2009) 16(2):161-71. doi:10.1016/j.ccr.2009.05.018.
22. Ando T, Xiao W, Gao P, Namiranian S, Matsumoto K, Tomimori Y, et al. Critical role for mast cell Stat5 activity in skin inflammation. Cell Rep (2014) 6(2):366-76. doi:10.1016/j.celrep.2013.12.029.
23. Knisz J, Banks A, McKeag L, Metcalfe DD, Rothman PB, Brown JM. Loss of SOCS7 in mice results in severe cutaneous disease and increased mast cell activation. Clin Immunol (2009) 132(2):277-84. doi:10.1016/j.clim.2009.04.003.
24. Kogan SC, Ward JM, Anver MR, Berman JJ, Brayton C, CardiffRD, et al. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood (2002) 100(1):238-45. doi:10.1182/blood. V100.1.238.
25. Kawada A, Hiruma M, Noguchi H, Ishibashi A, Motoyoshi K, Kawada I. Granulocyte and macrophage colony-stimulating factors stimulate proliferation of human keratinocytes. Arch Dermatol Res (1997) 289(10):600-2. doi:10.1007/s004030050246.
26. Liu YJ. Thymic stromal lymphopoietin: master switch for allergic inflammation. J Exp Med (2006) 203(2):269-73. doi:10.1084/jem.20051745.
27. Ziegler SF. Thymic stromal lymphopoietin and allergic disease. J Allergy Clin Immunol (2012) 130(4):845-52. doi:10.1016/j.jaci.2012.07.010.
28. Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol (2002) 3(7):673-80. doi:10.1038/ni805.
29. Yoo J, Omori M, Gyarmati D, Zhou B, Aye T, Brewer A, et al. Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. J Exp Med (2005) 202(4):541-9. doi:10.1084/jem.20041503.
30. Li M, Messaddeq N, Teletin M, Pasquali JL, Metzger D, Chambon P. Retinoid X receptor ablation in adult mouse keratinocytes generates an atopic dermatitis triggered by thymic stromal lymphopoietin. Proc Natl Acad Sci U S A (2005) 102(41):14795-800. doi:10.1073/pnas.0507385102.
31. Ando T, Matsumoto K, Namiranian S, Yamashita H, Glatthorn H, Kimura M, et al. Mast cells are required for full expression of allergen/SEB-induced skin inflammation. J Invest Dermatol (2013) 133(12):2695-705. doi:10.1038/jid.2013.250.
32. Wilson SR, The L, Batia LM, Beattie K, Katibah GE, McClain SP, et al. The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell (2013) 155(2):285-95. doi:10.1016/j.cell.2013.08.057.
33. Yasudo H, Ando T, Xiao W, Kawakami Y, Kawakami T. Short Stat5-interacting peptide derived from phospholipase C-beta3 inhibits hematopoietic cell proliferation and myeloid differentiation. PLoS One (2011) 6(9):e24995. doi:10.1371/journal.pone.0024995.
34. Jin X, Zhao W, Kirabo A, Park SO, Ho WT, Sayeski PP, et al. Elevated levels of mast cells are involved in pruritus associated with polycythemia vera in JAK2V617F transgenic mice. J Immunol (2014) 193(2):477-84. doi:10.4049/jimmunol.1301946.
35. Masuoka M, Shiraishi H, Ohta S, Suzuki S, Arima K, Aoki S, et al. Periostin promotes chronic allergic inflammation in response to Th2 cytokines. J Clin Invest (2012) 122(7):2590-600. doi:10.1172/JCI58978.
36. Soderberg KC, Hagmar L, Schwartzbaum J, Feychting M. Allergic conditions and risk of hematological malignancies in adults: a cohort study. BMC Public Health (2004) 4:51. doi:10.1186/1471-2458-4-51.
37. Talbot-Smith A, Fritschi L, Divitini ML, Mallon DF, Knuiman MW. Allergy, atopy, and cancer: a prospective study of the 1981 Busselton cohort. Am J Epidemiol (2003) 157(7):606-12. doi:10.1093/aje/kwg020.
38. Mills PK, Beeson WL, Fraser GE, Phillips RL. Allergy and cancer: organ site-specific results from the adventist health study. Am J Epidemiol (1992) 136(3):287-95.
39. Eriksson NE, Holmen A, Hogstedt B, Mikoczy Z, Hagmar L. A prospective study of cancer incidence in a cohort examined for allergy. Allergy (1995) 50(9):718-22. doi:10.1111/j.1398-9995.1995.tb01212.x.
40. McWhorter WP. Allergy and risk of cancer. A prospective study using NHANESI followup data. Cancer (1988) 62(2):451-5. doi:10.1002/1097-0142(19880715)62:2<451::AID-CNCR2820620234>3.0.CO;2-D.
41. Musolino C, Allegra A, Minciullo PL, Gangemi S. Allergy and risk of hematologic malignancies: associations and mechanisms. Leuk Res (2014) 38(10):1137-44. doi:10.1016/j.leukres.2014.08.004.
42. Koshiol J, Lam TK, Gridley G, Check D, Brown LM, Landgren O. Racial differences in chronic immune stimulatory conditions and risk of non-Hodgkin's lymphoma in veterans from the United States. J Clin Oncol (2011) 29(4):378-85. doi:10.1200/JCO.2010.30.1515.
43. Nunez-Enriquez JC, Fajardo-Gutierrez A, Buchan-Duran EP, Bernaldez-Rios R, Medina-Sanson A, Jimenez-Hernandez E, et al. Allergy and acute leukaemia in children with Down syndrome: a population study. Report from the Mexican inter-institutional group for the identification of the causes of childhood leukaemia. Br J Cancer (2013) 108(11):2334-8. doi:10.1038/bjc.2013.237.
44. Linabery AM, Jurek AM, Duval S, Ross JA. The association between atopy and childhood/adolescent leukemia: a meta-analysis. Am J Epidemiol (2010) 171(7):749-64. doi:10.1093/aje/kwq004.
45. Cohen PR. Sweet's syndrome-a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis (2007) 2:34. doi:10.1186/1750-1172-2-34.
46. Nesterovitch AB, Gyorfy Z, Hoffman MD, Moore EC, Elbuluk N, Tryniszewska B, et al. Alteration in the gene encoding protein tyrosine phosphatase nonreceptor type 6 (PTPN6/SHP1) may contribute to neutrophilic dermatoses. Am J Pathol (2011) 178(4):1434-41. doi:10.1016/j.ajpath.2010.12.035.
47. Mullighan CG, Collins-Underwood JR, Phillips LA, Loudin MG, Liu W, Zhang J, et al. Rearrangement of CRLF2 in B-progenitor-and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet (2009) 41(11):1243-6. doi:10.1038/ng.469.
48. Russell LJ, Capasso M, Vater I, Akasaka T, Bernard OA, Calasanz MJ, et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood (2009) 114(13):2688-98. doi:10.1182/blood-2009-03-208397.